Rohan Hockings

Former IKEA franchise owner Alan Tribe has taken charge at local biotech firm Phylogica, lifting his stake to 20 per cent and becoming chairman on the same day chief executive Stephanie Unwin was replaced by Rohan Hockings.

Phylogica has a new chief executive who is determined to bring the Perth biotech’s commercialisation strategy to fruition.

Shares in biomedical technology business Phylogica were up 13 per cent today after the company announced it had completed a $9.1 million recapitalisation.

Perth biotech Phylogica today announced positive test results from its drug delivery technology, but the news was not enough to sustain a rally in the company's shares, which have risen 33 per cent over the past week.

Phylogica has announced a commercial collaboration with Lions Eye Institute trading under the name Vision Pharma, bringing the biotechnology company a step closer to commercialising its drug delivery technology.

Biotech company PYC Therapeutics has sought funding for its lead drug development program that aims to treat childhood blindness.

The rising fortunes of biotech company PYC Therapeutics have bolstered the wealth of its major shareholders, most notably chairman Alan Tribe.

Four companies including VeinTech and Vision Pharma have been selected as finalists in the Great for the State category at the Innovator of the Year Awards.

A company targeting treatment of blindness was announced as the WA Innovator of the Year on Wednesday night.

The developer is seeking community input before submitting its plans for the vacant site.

GenusPlus Group managing director David Riches was named First Amongst Equals at the 2022 40under40 Awards, ahead of a diverse cohort of Western Australia’s young business leaders.

40under40: The journey from an idea to an approved medication is as difficult as putting a person on the moon, Rohan Hockings says.

Property developer Exal Group has bought a 31,100 square metre lot from a Chinese real estate group, as it progresses its plans for its project worth more than $500 million at the site.

Nedlands-based biotechnology company PYC Therapeutics has raised $30 million to progress its series of drug trials.

PYC Therapeutics is rattling the tin for up to $74.6 million to fund the progress of its medical drug trials, including for blinding eye and polycystic kidney diseases.

Perth biotech company PYC Therapeutics has hit a major milestone in the development of a first-in-class drug to treat a rare eye disease, recently receiving orphan drug designation from the US FDA.

Nedlands-based biotech company PYC Therapeutics is rattling the tin for up to $146 million to fund the progression of four novel drug candidates.